Pulmonary embolism is a common disease that is associated with significant mobility and mortality. Thrombolysis is potentially life saving when used in conjunction with anticoagulant therapy. Indications for thrombolysis for pulmonary embolism are not well defined. In patients with acute massive pulmonary embolism and hypotension, thrombolytic therapy offers some benefits in terms of mortality reduction. The use of thrombolysis in patients with stable haemodynamics has been controversial for more than two decades. Recent clinical studies have indicated that thrombolytic treatment in conjunction with heparin in patients with submassive pulmonary embolism and normal blood pressure can prevent deterioration of the disease and diminish the need for more intensive therapies during hospitalisation. The role of prehospital thrombolytic therapy for acute pulmonary embolism is unclear and further clinical studies are warranted.
SilversteinMD, HeitJA, MohrDN. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med1998; 158: 585–93.
2.
GoldhaberSZ, VisaniL, De RosaM. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet1999; 353:1386–9.
3.
KasperW, KonstantinidesS, GeibelA. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol1997; 30:1165–71.
4.
DalenJE, AlpertJS, HirschJ. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated?Arch Intern Med1997; 157:2550–6.
5.
QuinlanDJ, McQuillanA, EikelboomJW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for the treatment of pulmonary embolism: a meta-analysis of randomized controlled trials. Ann Intern Med2004; 140; 175–83.
6.
LevineMN, RaskobG, BeythRJ. Hemorrhagic complications of anticoagulant treatment. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004; 126: 287S–310S.
7.
GoldhaberS, ElliotC. Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. Circulation2003; 108: 2834–8.
8.
CrowtherMA, GinsbergJS, JulianJ. A comparison of two intensities of warfarin for prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. N Engl J Med2003; 349: 1133–8.
9.
BullerHR, AgnelliG, HullRD. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004; 126 (3 Suppl): 401S–28S.
10.
KonstantinidesS, GeibelA. Association between thrombolytic treatment and the prognosis of haemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation1997; 96:882–8.
Dalla-VoltaS, PallaA, SantolicandroA. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. J Am Coll Cardiol1992; 20:520–6.
14.
GoldhaberSZ, KesslerCM, HeitJ. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet1988; 2:293–8.
15.
MeyerG, SorsH, CharbonnierB. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol1992; 19:239–45.
16.
WanS, QuinlanDJ, AgnelliG, EikelboomJW. Thrombolysis compared with heparin for initial treatment of pulmonary embolism: a meta-analysis of randomized controlled trials. Circulation2004; 110: 744–49.
KonstantinidesS, GeibelA, HeuselG, HeinrichF, KasperW, for the Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med2002; 347:1143–50.
19.
KuismaM, SilfvastT, VoipioV, MalmstromR. Prehospital thrombolytic treatment of massive pulmonary embolism with reteplase during cardiopulmonary resuscitation. Resuscitation1998; 38: 47–50.
20.
SpohrF, ArntzHR, BluhmkiE. International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. Eur J Clin Invest2005; 35:315–23.
